We considered that the constitutive over-expression by cultured rheumatoid arthritis (RA) 
Genetic factors account for a significant proportion of the susceptibility to rheumatoid arthritis (RA). 1 A significant proportion of the genetic contribution to RA is accounted for by major histocompatibility complex (MHC) genes, particularly HLA-DRB1 alleles that encode the 'shared epitope' (SE). [1] [2] [3] However, little is known about the role of genes outside the MHC that may account for 50-70% of the genetic contribution to disease susceptibility. 1 While over 13 non-MHC loci have been identified with suggestive P values or LOD scores in linkage studies, [3] [4] [5] [6] [7] [8] only six loci could be replicated in a second study, [3] [4] [5] [6] 8 and no specific non-MHC genes have been identified.
We considered the combination of two alternative stra- tegies to maximize the candidate gene identification efforts. One used the differential expression of genes in the synovium or synovial cells from RA as compared with normal or osteoarthritis cells in order to identify candidate genes, and the other used non-MHC susceptibility loci identified in other autoimmune diseases as candidate genomic regions potentially harboring susceptibility genes in RA. We considered that at least some of the disease-causing alleles in complex traits like RA could be polymorphic variants that in their cis untranslated regulatory regions favor the binding of transcription factors, ultimately leading to increased gene expression and protein synthesis in certain tissues. In that case, gene expression profiling of disease tissues could provide clues for the identification of new susceptibility genes. Those candidate genes could then be used as candidate genes in either linkage or association analyses, and then screened for mutations/polymorphisms. Previous studies have described the clustering of non-MHC loci regulating different forms of autoimmune diseases in humans, or their homologous equivalents in rodent models of autoimmunity. [9] [10] [11] Those findings suggest that there may be common non-MHC genes regulating different forms of autoimmune diseases. Additional support for this possibility came from recent studies 111 reporting that at least seven of the non-MHC loci identified in linkage studies of RA families co-localized with regions regulating insulin-dependent diabetes mellitus (IDDM). 3, 4, 6, 12 We examined IGFBP5 (insulin-like growth factor binding protein 5) and its genomic location on chromosome 2q33-q36. IGFBP5 is expressed in high levels in cultured fibroblast-lineage synoviocytes (FLS) from RA patients, but is expressed in low amounts in cultured FLS from osteoarthritis patients. 13 Little is known about the function of IGFBP5 in the synovium; however, its involvement in the functional regulation and proliferation of other mesenchyme-originated cell lines like chondrocytes and myoblasts [14] [15] [16] suggests that it may also regulate FLS function.
The IGFBP5 region was also particularly interesting because it co-localized with IDDM13 on chromosome 2q33-q36, an IDDM susceptibility locus, 17, 18 raising the possibility that IGFBP5, or perhaps another gene located on 2q33-q36, could also be an important candidate susceptibility gene in RA. We studied the IGFBP5/IDDM13 region for linkage with RA.
Results and discussion
Forty-nine RA sibships were identified. Patient enrollment, demographic and clinical data, DNA extraction and HLA-DRB1 typing are depicted in Table 1 . In 44 (78.5%) sib pairs (including breaking the sibships with more than two affected offspring into all possible sib pairs 21 ) both siblings had at least one SE allele (group 1), and in 12 sib pairs at least one sibling was SE negative (group 2).
First, a two-point LOD score analysis was done using all 49 sibships and assuming two models (dominant or recessive). LOD score curves were completely negative under the dominant model for all three microsatellite 19 and were recruited from private rheumatology offices. Parents were not available for most of the pedigrees, therefore we were unable to check for non-paternity. There were no monozygotic twins. Sibships with a family history of systemic lupus erythematosus, Sjogren's syndrome, Juvenile RA, spondyloarthropathies or distal interphalangeal joint involvement were excluded. Only sibships with a rheumatoid factor positive proband were enrolled. DNA was extracted from peripheral blood mononuclear cells using either Qiagen (Valencia, CA, USA) or Gentra (Minneapolis, MN, USA) commercially available kits. HLA-DRB1 typing and allele assignment were done as described previously. 20 HLA-DRB1*0401, 0404, 0405, 0408, 0101 and 1402 were designated 'SE' positive. markers (Figure 1a) . Under the recessive model, the curves were completely negative for markers D2S339 and D2S137, and marker D2S301 obtained a maximum LOD score of 0.54 at zero recombination (Figure 1b) . The 'nonparametric' test resulted in P values of 0.5 for all three markers. Since previous studies suggested that an interaction between the MHC/HLA-DRB1 'shared-epitope' alleles and non-MHC loci in RA or rodent autoimmune arthritis may exist, we separated the sib-pairs into groups 1 and 2, as described above, according to SE status. However, the subset analysis also did not yield evidence for linkage. In each subgroup the LOD scores for D2S339 and D2S137 remained negative under both genetic models (results not shown). Under the recessive model, the maximum LOD score for D2S301 was 0.57 at zero recombination for group 1, compared to LOD scores of zero at all recombination fractions (ie, no linkage information) for group 2. Thus the non-significant positive LOD scores at D2S301 seen in the combined analysis appeared to be accounted for by the SE positive group.
The IGFBP5 gene maps to a region on chromosome 2q33-q36 implicated in the susceptibility to IDDM (IDDM13). 17, 18 The location of IGFBP5 in the IDDM13 interval, its increased expression is RA FLS, and the role of IGFBP5 in the functional regulation of other mesenchyme-derived cell lineages [14] [15] [16] made us consider it a good candidate gene which we tested for linkage. However, we found no evidence for linkage at the IGFBP5 region on chromosome 2q33-q36 in RA patients, despite the adjustment for the presence of the SE, a factor that could have interfered with the identification of non-MHC loci, as demonstrated in studies of RA and other autoimmune diseases. 4, 10, 11 Under optimistic assumptions (ie, assuming a multiplicative mode of inheritance with zero recombination between disease and the marker, and a disease allele frequency of 1%), our sample size would detect linkage with a disease locus that has a genotypic relative risk of 7, assuming 80% power and a type I error rate of 0.0001. However, the power plummets when we assume recombination and/or other modes of inheritance, such as recessive, for a genotypic relative risk of 7. Therefore, while our data makes it unlikely that 2q33-q36 harbors a major RA susceptibility locus, our data cannot exclude a susceptibility locus with a smaller contribution to RA susceptibility. On the other hand, the lack of evidence for linkage described herein is supported by a recent study by Myerscough et al 12 who also found no evidence for linkage at IDDM13 in RA extended pedigree families from England, and also, neither one of the four previous systematic genome-wide scans done in RA families identified evidence for linkage to the IDDM13 interval on chromosome 2q33-q36. We considered that in those studies, however, there was a possibility of lowdensity microsatellite marker coverage in the IDDM13/IGFBP5 region that could have contributed to the negative results.
3-6 Cornelis et al 4 described a P value of 0.024 for a single marker at the 2q33-q36 region (D2S377), but this level of significance does not reach the levels required for suggestive or definitive for linkage. 30 Furthermore, that study found no other markers in the 2q33-q36 region reaching statistical significance, even at the P value of 0.05, and from our analysis, LOD score curves for D2S339, which is located 0.8 cM from D2S377, were completely negative under both dominant and recessive modes of inheritance, supporting the concept Figure 1 Microsatellite-based primer pairs were identified from the Généthon primer database (ftp://ftp.genethon.fr/pub/Gmap/ Nature-1995/data/) and map (http://www.ncbi.nlm.nih.gov/ genemap/) to cover 11.2 cM in the IGFBP5 region. D2S137 is located at position 217.6 cM, 4.4 cM centromeric from IGFBP5, D2S301 is at 223.1 cM and co-localizes with IGFBP5 (theta = zero), and D2S339 is at 228.8 cM, 6.8 cM telomeric from IGFBP5, with 0.67, 0.80 and 0.77 heterozygozity, respectively. PCRs were set up in 10 l volume reactions as previously described 11 using fluorescent dCTPs at 0.5-2 M (PE Applied Biosystems, Foster City, CA, USA). PCR products were combined for electrophoresis in a 377 PE Automated sequencer. Gel analyses and automated allele assignment were done with GeneScan Analysis 3.1 and the Genotyper 1.1 (Foster City, CA), respectively. All allele assignments were manually re-checked by two investigators (PSG and WKC), and questionable genotypes that could not be clarified were repeated. Genotypes that could not be read or agreed upon after two repetitions were excluded from the analyses. Using the FASTLINK software package, 22 ,23 a two-point LOD score analysis was done under two models: a recessive and dominant mode of inheritance. Each model assumed 50% penetrance and a 0.1% phenocopy rate. The maximum of the two models was reported. [24] [25] [26] Heterogeneity was tested with the HOMOG program. 27 A 'nonparametric' affected sib pair analysis was also done with the SIBPAIR program from the ANALYZE package. 28 The general population allele frequency was estimated based on the study population allele distribution. 29 LOD score curves for markers D2S339 (solid line), D2S137 (dot-dashed line), and D2S301 (dotted line) assuming a dominant (a) or recessive (b) model. that this finding was most likely a false positive resulting from multiple tests. However, there is still the possibility that IGFBP5/IDDM13 could have a stronger effect in the regulation of disease severity as opposed to susceptibility, and the multicentric genetic studies in RA will likely be able to address that.
While the IGFBP5 increased expression in RA FLS did not lead to the identification of linkage, the use of differential gene expression studies to identify candidate genes for linkage analysis may still apply to other genes. For example, Rozzo et al 31 recently used oligonucleotide microarrays to identify a differentially expressed interferon-inducible gene (Ifi202) whose promoter polymorphisms appear to account for the genetic effect of the murine lupus locus Nba2, supporting this study's concept.
In conclusion, our findings, in conjunction with the negative results from other studies, strongly suggest that the chromosome 2q33-q36 region does not contain a RA susceptibility locus. These findings taken together suggest that, while there may be common genes regulating different forms of autoimmune diseases, there may also be certain genes that are disease-specific, perhaps involved in the regulation of organ/tissue-specific immune responses.
